Better Times Ahead For Cabaletta Bio Inc (NASDAQ: CABA)?

Cabaletta Bio Inc (CABA) concluded trading on Thursday at a closing price of $1.81, with 9.39 million shares of worth about $17.0 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.42% during that period and on May 15, 2025 the price saw a gain of about 39.23%. Currently the company’s common shares owned by public are about 50.74M shares, out of which, 45.71M shares are available for trading.

Stock saw a price change of 49.59% in past 5 days and over the past one month there was a price change of 61.61%. Year-to-date (YTD), CABA shares are showing a performance of -20.26% which decreased to -83.93% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.99 but also hit the highest price of $13.50 during that period. The average intraday trading volume for Cabaletta Bio Inc shares is 933.48K. The stock is currently trading 41.19% above its 20-day simple moving average (SMA20), while that difference is up 28.60% for SMA50 and it goes to -40.96% lower than SMA200.

Cabaletta Bio Inc (NASDAQ: CABA) currently have 50.74M outstanding shares and institutions hold larger chunk of about 68.57% of that.

The stock has a current market capitalization of $91.85M and its 3Y-monthly beta is at 2.65. It has posted earnings per share of -$2.34 in the same period. It has Quick Ratio of 6.15 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CABA, volatility over the week remained 12.66% while standing at 9.72% over the month.

Stock’s fiscal year EPS is expected to drop by -0.84% while it is estimated to increase by 9.07% in next year. EPS is likely to grow at an annualized rate of 5.64% for next 5-years, compared to annual growth of -20.35% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on December 20, 2024 offering an In-line rating for the stock and assigned a target price range of between $15 and $6 to it. Coverage by Wells Fargo stated Cabaletta Bio Inc (CABA) stock as an Equal weight in their note to investors on December 19, 2024, suggesting a price target of $6 for the stock. On October 10, 2024, UBS Initiated their recommendations, while on February 05, 2024, Jefferies Initiated their ratings for the stock with a price target of $36. Stock get an Outperform rating from William Blair on November 29, 2023.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.